Product

  • Jan. 31, 2012 biOasis Advances its Herceptin® BT2111 Program

    Vancouver, B.C.–(Business Wire)– biOasis Technologies Inc. (TSX:V.BTI) announced today that work is underway at Texas Tech University Health Sciences Center (TTUHSC) to perform a series of preclinical studies designed to evaluate the pharmacokinetics of BT2111 (a proprietary conjugate of p97 and Herceptin®) in animal models of breast cancer metastasis in the brain. The studies at… Read more »

  • Nov. 1, 2011 biOasis Transcend Vector Delivers an Anti-Amyloid Beta (A?) Antibody To The Brain

    Vancouver, BC–(Business Wire)– biOasis Technologies Inc. (TSX.V:BTI) today announced test results from its Transcend therapeutic development program directed towards the delivery of targeted therapeutic compounds to the brain which showed that Transcend can deliver an anti-amyloid beta antibody to the brain. The work was conducted on behalf of the Company by the National Research Council… Read more »

  • Oct. 17, 2011 biOasis Receives Final Results from BC Cancer Research Centre Herceptin® Studies

    Vancouver, BC–(Business Wire)– biOasis Technologies Inc. (TSX.V:BTI) announced today the results from two additional studies conducted by the BC Cancer Research Centre (BCCRC). The additional studies confirmed and extended earlier data showing that BT2111, a conjugate made up of biOasis Transcend vector and trastuzumab (trade name Herceptin®), a humanized monoclonal antibody used clinically in the… Read more »

  • Jul. 6, 2011 biOasis Announces Transcend Vector Results with a Therapeutic Antibody That Targets Metastatic Breast Cancer

    Vancouver, BC–(Business Wire)– biOasis Technologies Inc. (TSX.V:BTI) today announced results from two studies designed to assess the therapeutic potential of its Transcend vector in treating metastatic breast cancer. In these studies trastuzumab (tradename Herceptin®), a humanized monoclonal antibody used clinically in the treatment of HER2-positive (“HER2+”) breast cancer, was chemically linked to the Transcend delivery… Read more »

  • May. 12, 2011 biOasis Initiates Transcend Vector Program Targeting Treatments for CNS Symptoms of Lysosomal Storage Disorders

    Vancouver, British Columbia–(Business Wire)– biOasis Technologies Inc. (TSX:V.BTI) announced today the initiation of its first Transcend therapeutic development program directed towards developing treatments for the neurological effects of lysosomal storage disorders (“LSD”). This strategic decision is based on recently announced results from the National Research Council of Canada demonstrating that intravenously administered Transcend is delivered… Read more »

  • May. 3, 2011 biOasis Receives Verification That Transcend Localizes To a Number of Cell Types in the Brain

    Vancouver, British Columbia–(Business Wire)– biOasis Technologies Inc. (TSX:V BTI) has received further experimental results from research performed on behalf of the Company by the National Research Council of Canada (“NRC”). This work was performed for the purpose of providing independent confirmation of results generated in prior work conducted by the Company. As reported previously, the… Read more »

  • Apr. 15, 2011 biOasis Receives Significant Independent Results From its Transcend Program

    Vancouver, British Columbia–(Business Wire)– biOasis Technologies Inc. (TSX:V BTI) has received experimental results from research performed on behalf of the Company by the National Research Council of Canada (“NRC”). This work was performed for the purpose of providing independent confirmation of results generated in prior work conducted by the Company. The NRC study used the… Read more »

  • Mar. 1, 2011 CognitestTM – Diagnostic Blood Test for Alzheimer’s disease – Milestone Attained

    Vancouver, British Columbia–(Business Wire)– biOasis Technologies Inc. (TSX,V:BTI) is pleased to announce the completion of a project intended to produce proprietary monoclonal antibodies (mAbs) for its CognitestTM blood test for Alzheimer’s disease. Highlights: Simple, easy to use diagnostic blood test for Alzheimer’s ready for clinical testing Human sample testing starting and to run over the… Read more »